

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :

C07C 311/00

A2

(11) International Publication Number:

WO 00/39077

(43) International Publication Date:

6 July 2000 (06.07.00)

(21) International Applicant

(22) International Filing Date

Hangeland et al.
102241-101

Express Mail: EL662089097US

Mailed: June 20, 2001

(30) Priority Data:
9828442.5

JC17 Rec'd PCT/PTO 20 JUN 2001

(71) Applicant (for all des):
AB [SE/SE]; Novu

(72) Inventors; and

(75) Inventors/Applicants


[US/US]; 234 Lou
ZHANG, Minsher
Warren, NJ 07059
24 Coral Tree C
RYONO, Denis [U
NJ 08540 (US). LI
S-141 31 Hudding
garvagen 53, S-1
Smedvagen 23, S
[IN/SE]; Barkväg
Chris [IN/SE]; SGARCIA COLLAZO, Ana Maria [ES/SE]; Moregatan 10,
S-118 27 Stockholm (SE). KOEHLER, Konrad [US/SE];
Visatravagen 27, S-141 50 Huddinge (SE).Certificate of Express Mailing
Transmittal Letter (in duplicate)
Preliminary Examination Report
PCT Request
PCT Demand
International Search Report
Unsigned Oath & Declaration
Notification of Receipt
Published Application WO 00/39007

09/868889

BG,
EE,
JP,
MA,
RU,
UG,
KE,
(AM,
(AT,
LU,
CM,Please, check the
WO 00/39077 different
from the postcard.

lished

(54) Title: NOVEL THYROID RECEPTOR LIGANDS AND METHOD II



(57) Abstract

New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R₁ is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R₂ and R₃ are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R₂ and R₃ being other than hydrogen; R₄ is a carboxylic acid amide (CONR'R'') or an acylsulphonamide (CONHSO₂R') derivative, or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof; or when n is equal to or greater than one, R₄ may be a heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR'R''). R₅ is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R₅=H). In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T₃-regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T₃ regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.

BEST AVAILABLE COPY